Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Gilead Sciences, Inc.

Advances In™: The Evolving Role of Antibody-Drug Conjugates for Treatment of TNBC

Release Date: October 1, 2021
Expiration Date: October 1, 2022

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the role of antibody-drug conjugates (ADCs) for the management of triple negative breast cancer (TNBC), with a forward-looking perspective on how new and novel agents might impact clinical practice. The essentials of the design and mechanism of action of ADCs, clinical data regarding current and emerging treatment strategies for TNBC, , and the management of ADC-related toxicities will be presented in a multimedia format, including a series of video interviews with an expert thought leader integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Gilead Sciences, Inc.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is directed toward oncologists involved in the treatment and management of triple negative breast cancer (TNBC). Fellows, nurses, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with TNBC will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Determine the mechanism of action of antibody-drug conjugates (ADCs) and the therapeutic rationale for using these agents in the treatment of triple negative breast cancer (TNBC)
Evaluate recent clinical trial data on the efficacy and safety of ADCs in the treatment of metastatic TNBC
Integrate available ADCs into individualized treatment plans for patients with metastatic TNBC
Develop strategies to mitigate and manage adverse events(AEs) in patients with metastatic TNBC who receive treatment with ADCs

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities

Faculty

Aditya Bardia, MD, MPH
Director, Breast Cancer Research Program,
Associate Professor, Harvard Medical School,
Co-Director, Pulmonary Vascular Disease Program
Attending Physician, Medical Oncology, Massachusetts General Hospital
Boston, MA

Disclosures: Grant/Research Support (Institutions): Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics, Daiichi Pharma/AstraZeneca. Consultant (Institutions): Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics, Taiho, Sanofi, Daiichi Pharma/AstraZeneca, Puma, Biotheranostics Inc, Phillips, Eli Lilly, Foundation Medicine.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.